These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21029965)

  • 1. Malaria vaccine design: immunological considerations.
    Good MF; Doolan DL
    Immunity; 2010 Oct; 33(4):555-66. PubMed ID: 21029965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunological challenge to developing a vaccine to the blood stages of malaria parasites.
    Good MF; Stanisic D; Xu H; Elliott S; Wykes M
    Immunol Rev; 2004 Oct; 201():254-67. PubMed ID: 15361246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-erythrocytic malaria vaccines to prevent Plasmodium falciparum malaria.
    Ballou WR; Kester KE; Heppner DG
    Chem Immunol; 2002; 80():253-61. PubMed ID: 12058643
    [No Abstract]   [Full Text] [Related]  

  • 4. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model.
    Doolan DL; Hoffman SL
    J Immunol; 1999 Jul; 163(2):884-92. PubMed ID: 10395683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malaria vaccine development using synthetic peptides as a technical platform.
    Corradin G; Céspedes N; Verdini A; Kajava AV; Arévalo-Herrera M; Herrera S
    Adv Immunol; 2012; 114():107-49. PubMed ID: 22449780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines.
    Dobaño C; Rogers WO; Gowda K; Doolan DL
    Immunol Lett; 2007 Aug; 111(2):92-102. PubMed ID: 17604849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in DNA-based heterologous prime-boost immunization strategies for malaria.
    Moore AC; Hill AV
    Immunol Rev; 2004 Jun; 199():126-43. PubMed ID: 15233731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.
    Patarroyo ME; Patarroyo MA
    Acc Chem Res; 2008 Mar; 41(3):377-86. PubMed ID: 18266328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exoerythrocytic malaria vaccine development: understanding host-parasite immunobiology underscores strategic success.
    Taylor-Robinson AW
    Expert Rev Vaccines; 2002 Oct; 1(3):317-40. PubMed ID: 12901572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preerythrocytic malaria vaccine development.
    Mikolajczak SA; Aly AS; Kappe SH
    Curr Opin Infect Dis; 2007 Oct; 20(5):461-6. PubMed ID: 17762778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17kDa.
    Dobaño C; Doolan DL
    Mol Immunol; 2007 Apr; 44(11):3037-48. PubMed ID: 17303242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A whole parasite vaccine to control the blood stages of Plasmodium: the case for lateral thinking.
    Good MF
    Trends Parasitol; 2011 Aug; 27(8):335-40. PubMed ID: 21514227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and parasitological studies on immunity to Plasmodium falciparum malaria in children.
    Høgh B
    Scand J Infect Dis Suppl; 1996; 102():1-53. PubMed ID: 9060051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
    Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
    Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing immune responses against Plasmodium for rational vaccine design.
    Douradinha B; Doolan DL
    Trends Parasitol; 2011 Jun; 27(6):274-83. PubMed ID: 21531627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malaria vaccines: are we getting closer?
    Epstein JE; Giersing B; Mullen G; Moorthy V; Richie TL
    Curr Opin Mol Ther; 2007 Feb; 9(1):12-24. PubMed ID: 17330398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
    Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
    N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can malaria DNA vaccines on their own be as immunogenic and protective as prime-boost approaches to immunization?
    Hoffman SL; Doolan DL
    Dev Biol (Basel); 2000; 104():121-32. PubMed ID: 11713810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria.
    Rainczuk A; Scorza T; Spithill TW; Smooker PM
    Infect Immun; 2004 Oct; 72(10):5565-73. PubMed ID: 15385453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmodium: mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity.
    Dobaño C; Sedegah M; Rogers WO; Kumar S; Zheng H; Hoffman SL; Doolan DL
    Exp Parasitol; 2009 Jun; 122(2):112-23. PubMed ID: 19249301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.